NasdaqCM - Nasdaq Real Time Price USD

Notable Labs, Ltd. (NTBL)

1.1950 -0.0550 (-4.40%)
At close: May 13 at 4:00 PM EDT
1.1000 -0.09 (-7.56%)
Pre-Market: 5:42 AM EDT
Loading Chart for NTBL
DELL
  • Previous Close 1.2500
  • Open 1.2300
  • Bid 1.1500 x 100
  • Ask 1.2400 x 100
  • Day's Range 1.0900 - 1.2400
  • 52 Week Range 0.8330 - 11.2000
  • Volume 424,425
  • Avg. Volume 402,316
  • Market Cap (intraday) 10.777M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -3.4100
  • Earnings Date May 14, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.00

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

www.notablelabs.com

16

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NTBL

Performance Overview: NTBL

Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NTBL
36.77%
S&P 500
9.47%

1-Year Return

NTBL
83.74%
S&P 500
26.61%

3-Year Return

NTBL
98.24%
S&P 500
28.51%

5-Year Return

NTBL
97.26%
S&P 500
81.21%

Compare To: NTBL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NTBL

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    10.78M

  • Enterprise Value

    1.00M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.73

  • Price/Book (mrq)

    0.71

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -73.13%

  • Return on Equity (ttm)

    -166.90%

  • Revenue (ttm)

    310k

  • Net Income Avi to Common (ttm)

    -11.26M

  • Diluted EPS (ttm)

    -3.4100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.82M

  • Total Debt/Equity (mrq)

    14.63%

  • Levered Free Cash Flow (ttm)

    -10.06M

Research Analysis: NTBL

Company Insights: NTBL

Research Reports: NTBL

People Also Watch